Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have eme...
| Autores: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Tipo de documento: | Artículo |
| Estado: | Published version |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repositorio: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p5046 |
| Acceso en línea: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | dermatomyositis cancer autoantibody diagnosis immunoassay |
| _version_ | 1878731335166590976 |
|---|---|
| author | Mariscal, A |
| author2 | Milan, M Baucells, A Martinez, MA Guillen, AG Trallero-Araguas, E Alvarado-Cardenas, M Martinez-Martinez, L Alserawan, L Franco-Leyva, T Sanz-Martinez, MT Vinas-Gimenez, L Corominas, H Juarez, C Castellvi, I Selva-O'Callaghan, A |
| author2_role | author author author author author author author author author author author author author author author |
| author_browse | Alserawan, L Alvarado-Cardenas, M Baucells, A Castellvi, I Corominas, H Franco-Leyva, T Guillen, AG Juarez, C Mariscal, A Martinez, MA Martinez-Martinez, L Milan, M Sanz-Martinez, MT Selva-O'Callaghan, A Trallero-Araguas, E Vinas-Gimenez, L |
| author_facet | Mariscal, A Milan, M Baucells, A Martinez, MA Guillen, AG Trallero-Araguas, E Alvarado-Cardenas, M Martinez-Martinez, L Alserawan, L Franco-Leyva, T Sanz-Martinez, MT Vinas-Gimenez, L Corominas, H Juarez, C Castellvi, I Selva-O'Callaghan, A |
| author_role | author |
| collection | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| description | Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma. Methods We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay. Results A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_2d85b6d2fcce299e91c784c4db162a5f |
| institution | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| instname_str | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:iibsantpau.fundanetsuite.com:p5046 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | FRONTIERS MEDIA SA |
| publisherStr | FRONTIERS MEDIA SA |
| reponame_str | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| spelling | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice Mariscal, A Milan, M Baucells, A Martinez, MA Guillen, AG Trallero-Araguas, E Alvarado-Cardenas, M Martinez-Martinez, L Alserawan, L Franco-Leyva, T Sanz-Martinez, MT Vinas-Gimenez, L Corominas, H Juarez, C Castellvi, I Selva-O'Callaghan, A dermatomyositis cancer autoantibody diagnosis immunoassay Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma. Methods We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay. Results A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method. FRONTIERS MEDIA SA https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046 |
| spellingShingle | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice Mariscal, A dermatomyositis cancer autoantibody diagnosis immunoassay |
| status_str | publishedVersion |
| title | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| title_full | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| title_fullStr | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| title_full_unstemmed | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| title_short | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| title_sort | Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice |
| topic | dermatomyositis cancer autoantibody diagnosis immunoassay |
| topic_facet | dermatomyositis cancer autoantibody diagnosis immunoassay |
| url | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046 |